Journal
CANCER CELL
Volume 40, Issue 10, Pages 1145-+Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.08.016
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [P30-CA076292, R01-CA184185, R01-CA233512, R01-CA262121, P01-CA250984]
- Florida Department of Health [20B04]
Ask authors/readers for more resources
The deletion or inhibition of PERK in cancer cells triggers activation of anti-tumor T cell immunity, attenuates tumor growth, and promotes immunogenic cell death. This mechanism provides a potential new target for cancer immunotherapy.
Activation of unfolded protein responses (UPRs) in cancer cells undergoing endoplasmic reticulum (ER) stress promotes survival. However, how UPR in tumor cells impacts anti-tumor immune responses remains poorly described. Here, we investigate the role of the UPR mediator pancreatic ER kinase (PKR)-like ER kinase (PERK) in cancer cells in the modulation of anti-tumor immunity. Deletion of PERK in cancer cells or pharmaco-logical inhibition of PERK in melanoma-bearing mice incites robust activation of anti-tumor T cell immunity and attenuates tumor growth. PERK elimination in ER-stressed malignant cells triggers SEC61b-induced parapto-sis, thereby promoting immunogenic cell death (ICD) and systemic anti-tumor responses. ICD induction in PERK-ablated tumors stimulates type I interferon production in dendritic cells (DCs), which primes CCR2-dependent tumor trafficking of common-monocytic precursors and their intra-tumor commitment into mono-cytic-lineage inflammatory Ly6C+CD103+ DCs. These findings identify how tumor cell-derived PERK promotes immune evasion and highlight the potential of PERK-targeting therapies in cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available